Join the Oncology Voice Network. Join for Free
Finding MSL Success in Cross Therapeutic Transitions
medical science liaison therapeutic area transition key opinion leaders leveraging transferable skills building professional relationships

Finding MSL Success in Cross Therapeutic Transitions


Share This Article


Summary

In this episode, Tom Caravela welcomes Mitch D'Rosario and Deanna Tucker to discuss the intricacies of switching therapeutic areas as a Medical Science Liaison (MSL). They share personal experiences and address common concerns when transitioning into new therapeutic spaces. The conversation delves into strategies for gaining expertise, accessing Key Opinion Leaders (KOLs), and overcoming challenges unique to different therapeutic areas. The guests emphasize the importance of leveraging transferable skills and relationship equity to establish credibility. They also touch on the impact of AI on MSL job applications and offer insights on adding value to KOLs. The episode concludes with reflections on building strong professional relationships.

Key Points

  • Transitioning between therapeutic areas can be daunting, but leveraging core MSL skills, such as pre-call planning and building relationships, is crucial for success.
  • Humility and a willingness to learn are essential when switching therapeutic areas, as they help build credibility with new KOLs and adapt to new scientific landscapes.
  • Leveraging your network and showcasing your transferable skills and experience can significantly aid in making a successful therapeutic area transition.

Click for Source
medical science liaison, therapeutic area transition, key opinion leaders, leveraging transferable skills, building professional relationships

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN